Alpha Cognition Inc. ACOG
8.62 USD -0.11 (-1.26%)
At closeNov 11, 2026, 4:26 PM EST
8.66 +0.04 +0.46%
After hours · Nov 11, 4:26 PM ET
8.60 Day range 9.00
4.50 52-week range 10.14
- YTD
- +32.62%
- 1 year
- +40.85%
News
zacks.com Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Beats Revenue Estimates Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.3 per share a year ago.
marketbeat.com What Alpha Cognition (ACOG) Said on Its Q3 Earnings Call Alpha Cognition NASDAQ: ACOG reported third-quarter 2026 net product revenue of approximately $7.8 million, up 30% from the preceding quarter, as prescriptions and prescriber adoption increased for…
benzinga.com Alpha Cognition Q3 2026 Earnings Call Transcript Alpha Cognition (NASDAQ:ACOG) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Alpha Cognition Q3 EPS $(0.35) Misses $(0.34) Estimate, Sales $7.777M Beat $7.040M Estimate Alpha Cognition (NASDAQ:ACOG) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 6.06 percent. This is a 16.67 percent decrease over losses of…
businesswire.com Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and…
businesswire.com Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing and commercializing novel…
businesswire.com Alpha Cognition to Participate in Upcoming Investor Events VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing and commercializing…
businesswire.com Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today…
businesswire.com Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL® VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing…
defenseworld.net Alpha Cognition Inc. (NASDAQ:ACOG) Receives Average Recommendation of “Buy” from Brokerages Shares of Alpha Cognition Inc. (NASDAQ: ACOG - Get Free Report) have earned a consensus rating of "Buy" from the five brokerages that are covering the stock, Marketbeat reports. Five investment…
businesswire.com Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing…
businesswire.com Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel…
benzinga.com Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or Rivastigmine Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using
businesswire.com Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an…
defenseworld.net Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI) Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) and Alpha Cognition (NASDAQ: ACOG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
defenseworld.net Analysts Set Alpha Cognition Inc. (NASDAQ:ACOG) Target Price at $18.00 Alpha Cognition Inc. (NASDAQ: ACOG - Get Free Report) has received an average rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat.com reports. Five investment…
businesswire.com Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel…
businesswire.com Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel…
benzinga.com This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page for full details and stock recommendations.
benzinga.com B. Riley Securities Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $21 B. Riley Securities analyst William Woods initiates coverage on Alpha Cognition (NASDAQ:ACOG) with a Buy rating and announces Price Target of $21.
benzinga.com HC Wainwright & Co. Maintains Buy on Alpha Cognition, Raises Price Target to $20 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Alpha Cognition (NASDAQ:ACOG) with a Buy and raises the price target from $18 to $20.
newsfilecorp.com Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26 Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's…
seekingalpha.com Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
zacks.com Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.
marketbeat.com Alpha Cognition Q2 Earnings Call Highlights Alpha Cognition NASDAQ: ACOG reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the…
benzinga.com Alpha Cognition Q2 2026 Earnings Call Transcript Alpha Cognition (NASDAQ:ACOG) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…- benzinga.com Alpha Cognition Q2 EPS $(0.40) Misses $(0.39) Estimate, Sales $6.092M Beat $4.384M Estimate Alpha Cognition (NASDAQ:ACOG) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) by 2.56 percent. This is a 38.46 percent increase over losses of…
businesswire.com Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for…
benzinga.com This Travelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. Consider buying TRV stock, analysts have Buy rating.
benzinga.com Raymond James Initiates Coverage On Alpha Cognition with Outperform Rating, Announces Price Target of $20 Raymond James analyst Ryan Deschner initiates coverage on Alpha Cognition (NASDAQ:ACOG) with a Outperform rating and announces Price Target of $20.
benzinga.com Alpha Cognition Appoints Robert Wills As Board Chairman, Succeeding Len Mertz Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today…
benzinga.com Alpha Cognition Enrolls First Patient In RESOLVE, Phase 4 Post-Marketing Clinical Study To Further Evaluate Tolerability Profile, Treatment Experience Associated With ZUNVEYL In Routine Clinical Practice Alpha Cognition, Inc. (ACOG: NASDAQ) ("Alpha Cognition" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the…- benzinga.com Alpha Cognition Reports Top-Line Results From BEACON Real-World Study Of ZUNVEYL Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYLProviders reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Maxim Group Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $12 Maxim Group analyst Naz Rahman initiates coverage on Alpha Cognition (NASDAQ:ACOG) with a Buy rating and announces Price Target of $12.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $18 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Alpha Cognition (NASDAQ:ACOG) with a Buy and maintains $18 price target.
- benzinga.com Full Transcript: Alpha Cognition Q1 2026 Earnings Call
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Alpha Cognition Q1 EPS $(0.32) Beats $(0.39) Estimate, Sales $3.534M Beat $3.423M Estimate Alpha Cognition (NASDAQ:ACOG) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.39) by 17.95 percent. This is a 146.15 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $18 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Alpha Cognition (NASDAQ:ACOG) with a Buy and maintains $18 price target.
- benzinga.com Craig-Hallum Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $14 Craig-Hallum analyst Chase Knickerbocker initiates coverage on Alpha Cognition (NASDAQ:ACOG) with a Buy rating and announces Price Target of $14.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Alpha Cognition Q4 EPS $(0.30) Misses $(0.27) Estimate, Sales $2.793M Miss $3.197M Estimate Alpha Cognition (NASDAQ:ACOG) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 41.18 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Alpha Cognition Enrolls First Participant In BEACON Trial To Evaluate ZUNVEYL Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Alpha Cognition Targets 2,000 ZUNVEYL Prescribers In 2026; Plans 3 Long-Term Care Alzheimer's Studies; Anticipates $3M Asia Licensing Milestone; Aims For Operating Profitability In 2027 ZUNVEYL prescriber base expected to expand to approximately 2,000 prescribing healthcare providers, and an increase in nursing home penetrationCompany expects to complete and/or initiate three…